Company Description
Oncology is OSI Pharmaceuticals' top priority. The company's FDA-approved Tarceva treats non-small cell lung cancer and pancreatic cancer and is...
Key OSI Pharmaceuticals Financials
| Company Type | Public - NASDAQ (GS): OSIP Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $341.0 |
| 2007 Employees | 488 |
More OSI Pharmaceuticals Financials (11 pages)
Latest OSI Pharmaceuticals Jobs jobs by Indeed
Competition
Competitive Landscape for Chemicals
Demand is driven by the health of the US economy because chemicals are used to make a wide variety of industrial and consumer products. The profitability of individual companies is closely tied to...
Read more about OSI Pharmaceuticals's competition across multiple industries
Top OSI Pharmaceuticals Competitors
Sponsored Links
The Business Directory
OSI Pharmaceuticals Executives
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Robert A. (Bob) Ingram | Network | E-mail |
| CEO and Director | Colin Goddard | Network | E-mail |
| EVP, CFO, and Treasurer | Michael G. (Mike) Atieh | Network | E-mail |
More OSI Pharmaceuticals Executives
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current OSI Pharmaceuticals News
- Cancer drugs come up short [Newsday (Melville, NY)] (07 Oct 2008 04:00:00 EDT)
- BioWorld Today October 7, 2008 [BioWorld Today] (07 Oct 2008 00:01:00 EDT)
- Briefing.com: Hourly In Play (R) - 23:00 ET [Briefing.com] (06 Oct 2008 23:00:00 EDT)
Sponsored Opportunity
